ライフサイエンスコーパス: lamotrigine

1 at age 26 years or older (24% valproate, 22% lamotrigine).

2 py (phenytoin, carbamazepine, valproate, and lamotrigine).

3 ilepsy through transport of carbamazepine or lamotrigine.

4 crease in dollars spent on cocaine, favoring lamotrigine.

5 seizures was reported for carbamazepine and lamotrigine.

6 arbamazepine, fluoxetine, amitriptyline, and lamotrigine.

7 single dose of phenobarbital, phenytoin, or lamotrigine.

8 treated with ethosuximide, valproic acid, or lamotrigine.

9 ly decreased sensitivity to 8-bromo-cAMP and lamotrigine.

10 1 indicated that an event was more likely on lamotrigine.

11 maceuticals, such as the anticonvulsant drug lamotrigine.

12 with lithium, antipsychotics, valproate, and lamotrigine.

13 ed to another commonly used mood stabilizer, lamotrigine.

14 c symptoms was reduced with lithium, but not lamotrigine.

15 Folic acid seems to nullify the effect of lamotrigine.

16 MCM rate with increasing dose was found with lamotrigine.

17 apy exposure to valproate, carbamazepine and lamotrigine.

18 nificant advantage for carbamazepine against lamotrigine (0.91 [0.77-1.09]), topiramate (0.86 [0.72-1

19 9%; 5-year RD for initiation of valproate vs lamotrigine, 0.18%; 95% CI, -0.09% to 0.49%).

20 5-year RD for initiation of oxcarbazepine vs lamotrigine, 0.29%; 95% CI, -0.12% to 0.69%; 5-year RD f

21 acosamide, -0.23 (0.07) mug/L/mg (P < .001); lamotrigine, -0.20 (0.02) mug/L/mg (P < .001); levetirac

22 initial daily maintenance doses advised were lamotrigine 1.5 mg/kg twice per day, levetiracetam 20 mg

23 significant difference between valproate and lamotrigine (1.25 [0.94-1.68]).

24 .15%), and 27 of the 1945 infants exposed to lamotrigine (1.39%).

25 valproate was significantly better than both lamotrigine (1.55 [1.07-2.24] and topiramate (1.89 [1.32

26 Lamotrigine, 10,11,-dihydro-10,11,-dihydroxy-carbamazepi

27 re discontinued, patients were randomized to lamotrigine (100-400 mg daily), lithium (0.8-1.1 mEq/L),

28 n to carbamazepine (105, 102-108; p=0.0015), lamotrigine (108, 105-110; p=0.0003), or phenytoin (108,

29 ported by 108 (33%) participants who started lamotrigine, 144 (44%) participants who started levetira

30 signed to treatment with ethosuximide (156), lamotrigine (149), or valproic acid (148) were similar w

31 pregnancy were decreased by up to 56.1% for lamotrigine (15.60 mug/L/mg to 6.85 mug/L/mg; P < .001),

32 Lamotrigine (2.31% in 4195 pregnancies) and levetiraceta

33 children exposed to carbamazepine (1/50) or lamotrigine (2/30).

34 igine (29%; odds ratio with ethosuximide vs. lamotrigine, 2.66; 95% CI, 1.65 to 4.28; odds ratio with

35 8; P=0.35) and were higher than the rate for lamotrigine (29%; odds ratio with ethosuximide vs. lamot

36 5 to 4.28; odds ratio with valproic acid vs. lamotrigine, 3.34; 95% CI, 2.06 to 5.42; P<0.001 for bot

37 e highest doses of valproate (300 mg/kg) and lamotrigine (30 mg/kg) also elevated ICSS thresholds, an

38 e voltage-gated Na+ and Ca2+ channel blocker lamotrigine (300 mg) abolished these changes.

39 4 test days involving the administration of lamotrigine, 300 mg by mouth, or placebo 2 hours prior t

40 f developing T2D compared with initiation of lamotrigine (5-year risk difference [RD], 1.17%; 95% CI,

41 r the initial advised maintenance doses were lamotrigine 50 mg (morning) and 100 mg (evening), leveti

42 Most patients responded to lamotrigine (56%), followed by oxcarbazepine (46%), dulo

43 rall (185 [86%] of 215; p=0.0404) and in the lamotrigine (59 [83%] of 71; p=0.0287) and valproate (38

44 mized to double-blind maintenance treatment (lamotrigine, 59 patients; lithium, 46 patients; and plac

45 mazepine (95% CI 1.9% to 3.5%) and 2.3% with lamotrigine (95% CI 1.8% to 3.1%).

46 nts lower than the score of those exposed to lamotrigine (95% confidence interval [CI], 3.1 to 14.6;

47 the mean IQ was 101 for children exposed to lamotrigine, 99 for those exposed to phenytoin, 98 for t

48 In this study, we tested the hypothesis that lamotrigine, a drug reported to inhibit glutamate releas

49 the first report of water samples containing lamotrigine, a relatively new drug used for the treatmen

50 Spontaneous suppressor mutations blocking lamotrigine activity mapped solely to the poorly charact

51 , the reduction in serum NfH levels based on lamotrigine adherence points to a possible neuroprotecti

52 showed no difference, however based on serum lamotrigine adherence there was significant decline in N

53 8]; P < .001) and lower remission rates (eg, lamotrigine: adjusted OR, 0.67; 95% CI, 0.53-0.84; P < .

54 creased functional expression of R1648C, but lamotrigine also increased persistent sodium current evo

55 HA was more frequent with OD valproate than lamotrigine among those initiating treatment at age youn

56 Among the most cold sensitive was lamotrigine, an anticonvulsant drug.

57 participants were randomly assigned; 101 to lamotrigine and 101 to placebo.

58 ed to treatment (87 women and 33 men): 61 to lamotrigine and 59 to placebo.

59 with the binding of the anticonvulsant drug Lamotrigine and batrachotoxin are also seen in the modif

60 Lamotrigine and bupropion represent new treatments for n

61 m was to investigate transport of phenytoin, lamotrigine and carbamazepine by using seven in-vitro tr

62 -2.58 to 2.82]; p=0.931) for those receiving lamotrigine and folic acid.

63 or an AED that does not alter cP450 enzymes (lamotrigine and gabapentin) in monotherapy for 6 months

64 bipolar I disorder lost weight while taking lamotrigine and gained weight while taking lithium.

65 than a hundred aqueous samples analyzed and lamotrigine and its 2-N-glucuronide metabolite were most

66 channels up to 8-fold for the anticonvulsant lamotrigine and its congeners 227c89, 4030w92, and 619c8

67 ethod detection limits were 1 and 5 ng/L for lamotrigine and its metabolite, respectively.

68 treatment outcomes appeared to be better for lamotrigine and levetiracetam than for phenytoin.

69 d good seizure control and tolerability with lamotrigine and levetiracetam.

70 zures during pregnancy, and baseline dose of lamotrigine and levetiracetam.

71 d to assess the efficacy and tolerability of lamotrigine and lithium compared with placebo for the pr

72 Both lamotrigine and lithium were superior to placebo at prol

73 Both lamotrigine and lithium were superior to placebo for the

74 The structurally different anticonvulsant lamotrigine and one of its derivatives have a binding si

75 < 0.001), and levetiracetam was superior to lamotrigine and oxcarbazepine for retention (P < 0.001);

76 edom, but levetiracetam remained superior to lamotrigine and oxcarbazepine for retention (P < 0.001);

77 edom, but levetiracetam remained superior to lamotrigine and oxcarbazepine for retention (P < 0.02);

78 ude the increase in plasma concentrations of lamotrigine and phenobarbital caused by valproic acid.

79 No dose effects were seen for lamotrigine and phenytoin.

80 bserve a reduction in NfH levels between the Lamotrigine and placebo arms, however, the reduction in

81 omparing absolute changes in NfH between the lamotrigine and placebo group showed no difference, howe

82 Lamotrigine and placebo groups were similar demographica

83 Lamotrigine and placebo were significantly better tolera

84 activity was confirmed on the pharmaceutical lamotrigine and the industrial solvent chlorobenzene, si

85 Lamotrigine and topiramate are also thought to possess b

86 in children in our study overall and in the lamotrigine and valproate groups.

87 oapoptotic action (phenobarbital, phenytoin, lamotrigine) and without proapoptotic action (levetirace

88 hium, anticonvulsants, such as valproate and lamotrigine, and atypical antipsychotic drugs, such as q

89 atment with atypical antipsychotics, MBP and lamotrigine, and H-FABP and lithium.

90 s the first detections of an antidepressant, lamotrigine, and its major metabolite (2-N-glucuronide),

91 than aripiprazole+valproate, carbamazepine, lamotrigine, and lamotrigine+valproate, outperformed pla

92 ed than topiramate and more efficacious than lamotrigine, and should remain the drug of first choice

93 same enzymes (eg, tiagabine, valproic acid, lamotrigine, and topiramate).

94 in the United States: felbamate, gabapentin, lamotrigine, and topiramate.

95 ndomized double-blind trial of ethosuximide, lamotrigine, and valproate had short-term seizure outcom

96 We tested lacosamide, lamotrigine, and valproate in the rat ICSS test alone or

97 pproved for bipolar disorder (carbamazepine, lamotrigine, and valproate) are associated with an eleva

98 For focal epilepsy, oxcarbazepine and lamotrigine are first-line therapy, while levetiracetam

99 europrotection with tetrahydrocannabinol and lamotrigine are imminent; both will involve subjects wit

100 ole, aripiprazole once monthly, aripiprazole+lamotrigine, aripiprazole+valproate, asenapine, carbamaz

101 ability in drug PK in healthy adults, taking lamotrigine as a model drug.

102 This work establishes lamotrigine as a widely available chemical probe of bact

103 criteria and who initiated levetiracetam or lamotrigine as initial monotherapy.

104 y prescribed antiepileptic drugs (phenytoin, lamotrigine), as well as the cystic fibrosis transmembra

105 ith folic acid reducing the effectiveness of lamotrigine at 12 weeks.

106 ved a single 25-mg dose of immediate-release lamotrigine at the start of each period, with the brande

107 evere skin reactions; implicated agents were lamotrigine, azithromycin, carbamazepine, moxifloxacin,

108 ssociated with shorter seizure duration (eg, lamotrigine: beta coefficient [SE], -6.02 [1.08]; P < .0

109 nvulsant drugs phenytoin, carbamazepine, and lamotrigine block neuronal voltage-gated Na(+) channels,

110 verbal and executive functions compared with lamotrigine (but not carbamazepine or phenytoin).

111 Our data show that the TTC value of lamotrigine can be reached for a child at a daily consum

112 ated sodium channel (VGSC) blockers, such as lamotrigine, carbamazepine, and valproate, show therapeu

113 bilizing treatments of BD such as valproate, lamotrigine, carbamazepine, oxcarbazepine, antipsychotic

114 e proportion achieving a 12-month remission (lamotrigine-carbamazepine) is 0 (-8 to 7) and 5 (-3 to 1

115 zole, ketamine, memantine, N-acetylcysteine, lamotrigine, celecoxib, ondansetron) either in combinati

116 The pattern of lamotrigine changes during pregnancy in these women with

117 5 (-3 to 12), suggesting non-inferiority of lamotrigine compared with carbamazepine.

118 rogestagen contraceptive pill might decrease lamotrigine concentrations, which could worsen seizure c

119 c acid, the combination of levetiracetam and lamotrigine demonstrated a lower risk of TF compared wit

120 t every 12 h (200-800 mg total, identical to lamotrigine dose prior to study enrolment); after each 1

121 the USA who were receiving immediate-release lamotrigine dosed at 100 mg, 200 mg, 300 mg, or 400 mg t

122 generic drugs) on-market, immediate-release lamotrigine drug products.

123 lso review the epilepsy literature on use of lamotrigine during pregnancy.

124 occurred more frequently with valproate than lamotrigine, especially if medication was started at age

125 induction of glucuronidation activity toward lamotrigine, ethinyl estradiol, chenodeoxycholic acid, a

126 By contrast, lamotrigine exacerbated the seizure phenotype.

127 Results were similar when lamotrigine-exposed infants were used as the reference g

128 y, analyses that used children with paternal lamotrigine exposure as active comparator, and analyses

129 CI 98-103, Cmax 90% CI 99-105), showing that lamotrigine exposures were equivalent between the generi

130 f action on sodium channels, a member of the lamotrigine family, R-(-)-2,4-diamino-6-(fluromethyl)-5-

131 rugs selected for discussion are gabapentin, lamotrigine, felbamate, vigabatrin, and topiramate.

132 ncourage clinicians and patients to consider lamotrigine for bipolar depression, but also to be aware

133 Lamotrigine, gabapentin, topiramate, and oxcarbazepine a

134 compounds (e.g., buproprion, carbamazepine, lamotrigine) generally were more persistent relative to

135 lume per year was -3.18 mL (SD -1.25) in the lamotrigine group and -2.48 mL (-0.97) in the placebo gr

136 analysed for the primary endpoint: 52 in the lamotrigine group and 56 in the placebo group.

137 More women in the valproate group than the lamotrigine group developed (OD) in the prospective (54%

138 More women in the valproate group than the lamotrigine group developed PCOS (9 vs 2%; p = 0.007).

139 nce were experienced more by patients in the lamotrigine group than the placebo group.

140 MCM rate for high-dose lamotrigine (>400 mg daily) was lower than the MCM rate

141 women more than 2 years after menarche (177 lamotrigine, (HA) 186 valproate) to exclude OD the confo

142 Patients receiving lamotrigine had lower depression ratings and Clinical Gl

143 ted that the standard sodium channel blocker lamotrigine had modest activity against Na(v)1.1, while

144 Lamotrigine had no effects on neuronal excitability of e

145 Subjects receiving lamotrigine had no significant reductions in calcium or

146 While lamotrigine has a favourable profile compared with valpr

147 Lamotrigine has been increasingly prescribed in pregnanc

148 Lamotrigine has been shown to be an effective treatment

149 d as anticonvulsants (notably, valproate and lamotrigine) have therapeutic effects in bipolar and rel

150 Lithium salts and lamotrigine, however, had no effect.

151 2; 95% confidence interval [CI], 1.11-1.80), lamotrigine (HR, 1.84; 95% CI, 1.43-2.37), oxcarbazepine

152 the clinically effective anticonvulsant drug lamotrigine (IC50=27.7 microM), a proposed neurotransmit

153 s similar to or different from valproate and lamotrigine in a model of reward and elevated mood.

154 effects of ethosuximide, valproic acid, and lamotrigine in children with newly diagnosed childhood a

155 PBPK model was extrapolated to predict PK of lamotrigine in paediatric and hepatic impaired populatio

156 Prescribing of lamotrigine in pregnancy has steadily increased and has

157 s present new data on serial serum levels of lamotrigine in pregnant patients on lamotrigine monother

158 available on the need for dosage changes for lamotrigine in pregnant women with bipolar disorder.

159 in prophylaxis of mania and depression, and lamotrigine in prophylaxis (relapse polarity unspecified

160 de and valproic acid are more effective than lamotrigine in the treatment of childhood absence epilep

161 mmon anti-epileptic drugs (levetiracetam and lamotrigine) in an integrated manner.

162 safety and efficacy of a new anticonvulsant, lamotrigine, in adult patients with bipolar disorder who

163 Both phenytoin and lamotrigine increased functional expression of R1648C, b

164 However, lamotrigine increased the immediate mood-elevating effec

165 d safety of antidepressant augmentation with lamotrigine, inositol, and risperidone.

166 gned to open-label adjunctive treatment with lamotrigine, inositol, or risperidone for up to 16 weeks

167 son analyses of open-label augmentation with lamotrigine, inositol, or risperidone.

168 to assess whether the sodium-channel blocker lamotrigine is also neuroprotective in patients with sec

169 The results indicate that lamotrigine is an effective, well-tolerated maintenance

170 Lamotrigine is clinically better than carbamazepine, the

171 ffective in the treatment of acute mania and lamotrigine is effective at treating and preventing bipo

172 e for anticonvulsants such as divalproex and lamotrigine is less robust and there is much uncertainty

173 ailed analysis of the TPs, we suggested that lamotrigine is transformed mainly by oxidation, addition

174 prazole+valproate, asenapine, carbamazepine, lamotrigine, lamotrigine+valproate, lithium, lithium+oxc

175 Aripiprazole+valproate, lamotrigine, lamotrigine+valproate, lithium, olanzapine,

176 if combination therapy with quetiapine plus lamotrigine leads to greater improvement in depressive s

177 The change in serum lamotrigine levels in the postpartum period ranged from

178 Exposure to AEDs (carbamazepine, lamotrigine, levetiracetam, and sodium valproate) was de

179 rial comparing systematic with rescue TDM of lamotrigine, levetiracetam, oxcarbazepine, topiramate, b

180 In contrast, the new AEDs gabapentin, lamotrigine, levetiracetam, tiagabine, topiramate, vigab

181 atabase from two FDA registration studies of lamotrigine, lithium and placebo.

182 lysis was conducted to assess the effects of lamotrigine, lithium, and placebo administration on body

183 at week 52 were -4.2, +6.1, and -0.6 kg with lamotrigine, lithium, and placebo, respectively (lamotri

184 g) at week 52 were -0.5, +1.1, and +0.7 with lamotrigine, lithium, and placebo, respectively, with no

185 were suspect-screened for the anticonvulsant lamotrigine (LMG), its metabolites, and related compound

186 amazepine (CBZ) 0.43 (-0.19 to 1.05) p=0.17; lamotrigine (LTG) 0.31 (-0.38 to 1.00) p=0.38; levetirac

187 label data provide preliminary evidence that lamotrigine may be an effective treatment option for pat

188 Post hoc secondary analyses suggest that lamotrigine may be superior to inositol and risperidone

189 of AEDs; examples include the stimulation of lamotrigine metabolism by oral contraceptive steroids an

190 exiletine-lamotrigine sequence (n=30) or the lamotrigine-mexiletine sequence (n=30).

191 evels of lamotrigine in pregnant patients on lamotrigine monotherapy.

192 718 to carbamazepine monotherapy and 2198 to lamotrigine monotherapy.

193 ntibiotics (n = 25), ibuprofen (n = 15), and lamotrigine (n = 11).

194 mized to 12 months of valproate (n = 225) or lamotrigine (n = 222) therapy.

195 to degradation and that its human metabolite lamotrigine-N(2)-glucuronide (LMG-N2-G) is the actual so

196 mide (UCL 1684; K(+) channel antagonist) and lamotrigine (Na(+) channel antagonist) were found to sig

197 Neither lamotrigine nor carbamazepine was a substrate for P-gp i

198 eceived valproate, and 7588 (33.1%) received lamotrigine (not mutually exclusive).

199 Two detections for lamotrigine occurred in drinking water.

200 ints to a possible neuroprotective effect of lamotrigine on axonal degeneration.

201 The effect of lamotrigine on cerebral volume of patients with secondar

202 T-Na(V)1.1 and both mutant channels, whereas lamotrigine only increased surface expression of R1648C.

203 No P-gp interaction was observed for lamotrigine or carbamazepine in any of the seven validat

204 nt (carbamazepine, oxcarbazepine, phenytoin, lamotrigine or lacosamide) without evidence of symptom e

205 ted because 232 of 298 WWE (78%) were taking lamotrigine or levetiracetam alone or in combination.

206 334 offspring (2.5%) exposed to valproate vs lamotrigine or levetiracetam in Denmark, Norway, and Swe

207 nt to one of the noninducing anticonvulsants lamotrigine or levetiracetam.

208 re similar whether patients were switched to lamotrigine or levetiracetam.

209 and 513 in Norway (valproate: 169 offspring; lamotrigine or levetiracetam: 344 offspring), and found

210 th 648 in Denmark (valproate: 259 offspring; lamotrigine or levetiracetam: 389 offspring) and 513 in

211 participants were pretreated with 300 mg of lamotrigine or placebo and then were given the same dose

212 :1) by an adaptive minimisation algorithm to lamotrigine or placebo and to folic acid or placebo.

213 ticipants treated with phenytoin, valproate, lamotrigine, or carbamazepine were analyzed.

214 IQs among children exposed to carbamazepine, lamotrigine, or phenytoin but not among those exposed to

215 atients were randomly assigned to valproate, lamotrigine, or topiramate between Jan 12, 1999, and Aug

216 exposed to an antiepileptic (carbamazepine, lamotrigine, or valproate) or not exposed to an antiepil

217 sion valproate was significantly better than lamotrigine overall (0.76 [0.62-0.94]), and for the subg

218 nalysis suggests that the use of gabapentin, lamotrigine, oxcarbazepine, and tiagabine, compared with

219 We also prioritised clemastine, lamotrigine, oxcarbazepine, nimodipine and flunarizine.

220 signed to receive carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate.

221 signed to receive carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate.

222 ytoin, and valproate than in those receiving lamotrigine (p = 0.008).

223 ving phenytoin compared with those receiving lamotrigine (p = 0.017).

224 carries a significantly higher MCM risk than lamotrigine (p=0.0001) and carbamazepine (p=0.0001) mono

225 ge younger than 26 years (44% valproate, 23% lamotrigine; p = 0.002) but was similar if treatment was

226 e post hoc (HA) analyses (36% valproate, 23% lamotrigine; p = 0.007).

227 (OD) in the prospective (54% valproate, 38% lamotrigine; p = 0.010) and the post hoc (HA) analyses (

228 oss four commonly used drugs (carbamazepine, lamotrigine, phenytoin and valproate).

229 tiepileptic drug monotherapy (carbamazepine, lamotrigine, phenytoin, or valproate) between October, 1

230 a single antiepileptic agent (carbamazepine, lamotrigine, phenytoin, or valproate) in a prospective,

231 sy receiving monotherapy (ie, carbamazepine, lamotrigine, phenytoin, or valproate) were enrolled from

232 er 12 weeks than quetiapine monotherapy plus lamotrigine placebo.

233 ed HR, 2.41; 95% CI, 1.12-5.17; P = .02) and lamotrigine plus other ASM (adjusted HR, 4.03; 95% CI, 1

234 The combination of lamotrigine plus quetiapine potentially offers improved

235 Lamotrigine pretreatment prevented many of the BOLD sign

236 in to the noninducing drugs levetiracetam or lamotrigine produces rapid and clinically significant am

237 s received balanced doses of an oral generic lamotrigine product every 12 h (200-800 mg total, identi

238 omized participants, 49 (98%) received all 3 lamotrigine products and completed at least 3 pharmacoki

239 Disparate generic lamotrigine products in patients with epilepsy showed bi

240 ween two disparate generic immediate-release lamotrigine products in patients with epilepsy.

241 s study provides evidence that the disparate lamotrigine products studied are bioequivalent when test

242 Furthermore, the HCN channel agonist lamotrigine rescued the electrophysiological and cogniti

243 eal kindling, mesial temporal lobe epilepsy, lamotrigine-resistant amygdala kindling, as well as seiz

244 icantly better tolerated than carbamazepine (lamotrigine, RR 5.24, 1.07-26.32; placebo, RR 3.60, 1.04

245 fer from that of placebo over 24 months, but lamotrigine seemed to cause early volume loss that rever

246 pal slices, we found that the anticonvulsant lamotrigine selectively reduced action potential firing

247 s and observed a significant decrease in the lamotrigine-sensitive K(+) current, suggesting that the

248 1 and Dec 12, 2022, to either the mexiletine-lamotrigine sequence (n=30) or the lamotrigine-mexiletin

249 Compared with the third trimester, lamotrigine serum concentration increased an average of

250 The most dramatic increase in lamotrigine serum level early after delivery occurred at

251 Lamotrigine serum samples were obtained from eight mothe

252 Lamotrigine significantly decreased ketamine-induced per

253 In lamotrigine subjects, 1 ABCB1 missense polymorphism (rs2

254 in amount of cocaine use by self-report with lamotrigine suggests that a standard treatment for bipol

255 ned via a website by minimisation to receive lamotrigine (target dose 400 mg/day) or placebo for 2 ye

256 All of the women were taking lamotrigine throughout pregnancy.

257 , the prevalence of SGA ranged from 7.3% for lamotrigine to 18.5% for topiramate.

258 tion factor IF2 and prevented the binding of lamotrigine to IF2 in vitro.

259 Addition of lamotrigine to quetiapine treatment improved outcomes.

260 rial that compared initiating treatment with lamotrigine, topiramate and valproate in patients diagno

261 s converge on the consensus effectiveness of lamotrigine, topiramate, valproate, aripiprazole, olanza

262 d hippocampal NaV1.6 protein levels, whereas lamotrigine treatment had no effect on either pyramidal

263 Lamotrigine treatment reduced the deterioration of the t

264 Lamotrigine treatment resulted in the rapid accumulation

265 wever, in an exploratory modelling analysis, lamotrigine treatment seemed to be associated with great

266 Lamotrigine trial in SPMS was a randomised control trial

267 AChE inhibitors (tiapride, amisulpride, and lamotrigine), used as antipsychotic medicines, were iden

268 active treatments other than carbamazepine, lamotrigine+valproate (no data) and paliperidone outperf

269 oate, asenapine, carbamazepine, lamotrigine, lamotrigine+valproate, lithium, lithium+oxcarbazepine, l

270 Aripiprazole+valproate, lamotrigine, lamotrigine+valproate, lithium, olanzapine, and quetiapi

271 e+valproate, carbamazepine, lamotrigine, and lamotrigine+valproate, outperformed placebo for RR-mania

272 tine, and quetiapine) and the anticonvulsant lamotrigine; value and safety of antidepressants remain

273 trigine, lithium, and placebo, respectively (lamotrigine versus lithium and lithium versus placebo).

274 SR16 total score between the group receiving lamotrigine versus the placebo group at 12 weeks was -1.

275 poral lobe, 1.25, 1.06-1.47), and treatment (lamotrigine vs carbamazepine, 0.76, 0.61-0.95).

276 e time to intervention for any mood episode (lamotrigine vs placebo, P =.02; lithium vs placebo, P =.

277 However, the recovery rate with lamotrigine was 23.8%, whereas the recovery rates with i

278 In contrast to prior findings, high-dose lamotrigine was associated with fewer MCMs than all dose

279 In summary, lamotrigine was associated with limited therapeutic bene

280 At the delayed time point, pretreatment with lamotrigine was associated with lower perfusion in IFG.

281 In the second experiment, pretreatment with lamotrigine was compared with placebo to identify which

282 d, double-blind, placebo-controlled trial of lamotrigine was conducted in 120 outpatients with bipola

283 Lamotrigine was detected in 94% of all the wastewater sa

284 The most common adverse event reported for lamotrigine was headache.

285 not the result of translation inhibition, as lamotrigine was incapable of perturbing protein synthesi

286 open-label phase during which treatment with lamotrigine was initiated and other psychotropic drug re

287 Lamotrigine was selected as the antiepileptic drug of in

288 For time to treatment failure, lamotrigine was significantly better than carbamazepine

289 Lamotrigine was superior to placebo at prolonging the ti

290 Lamotrigine was taken once daily in doses ranging from 1

291 Lamotrigine was used as adjunctive therapy (N = 60) or m

292 iepileptic drugs and not currently receiving lamotrigine were enrolled between July 18, 2013, and Jan

293 with lithium, antipsychotics, valproate, and lamotrigine were identified.

294 es, among first-line ASMs, levetiracetam and lamotrigine were superior to oxcarbazepine for seizure f

295 e nonionic PCs (carbamazepine, caffeine, and lamotrigine) were detected at significantly higher conce

296 substantially attenuated for topiramate and lamotrigine, whereas an increased risk remained for valp

297 sensitive to modulation by pretreatment with lamotrigine, which inhibits glutamate release, a combina

298 Treatment with lamotrigine, which inhibits presynaptic release of gluta

299 The related compound lamotrigine, which is a better anticonvulsant but weaker

300 0 to -1.37]; p=0.004) for patients receiving lamotrigine without folic acid compared with 0.12 ([-2.5

301 Primary outcome was whether lamotrigine would significantly reduce detectable serum